With the development of new vaccines technologies—for example, mRNA vaccines—regulatory guidelines and industry standards need to evolve. Ensuring the quality of these vaccines and therapies is critical to meeting regulatory requirements, increasing access, and building public trust.

USP collaborates with scientific experts from the academic, industry, healthcare practitioner, and regulatory communities to address quality of these new therapies. USP standards and resources provide manufacturers with analytical methods that support quality throughout the development process. USP also offers regulators and national quality control laboratories benchmarks to ensure vaccine quality remains consistent from manufacturing through administration as they release new vaccines in their countries.

As regulatory guidelines and industry standards for new vaccines and therapies evolve, USP resources can help get products to market faster and ensures patients have access to the medicines that they need when they need them.